CTOs on the Move

Massachusetts Medical Society

www.massmed.org

 
The Massachusetts Medical Society is the oldest, most distinguished and prestigious continuously operating state medical association in the United States and the world.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.massmed.org
  • 860, Winter Street
    Waltham, MA USA 02451
  • Phone: 800.322.2303

Executives

Name Title Contact Details
Jacqui Boire
Director, Technology Strategy and Planning Profile

Similar Companies

Northwind Pharmaceuticals

Northwind provides a complete pharmaceutical dispensing solution for medical clinics coast to coast, from packaging to software. Learn more.

Envigo

Envigo provides essential products and research services for pharmaceutical, crop protection, and chemical companies as well as universities, governments, and other research organizations.

Innoviant Pharmacy

Innoviant Pharmacy is a Huntingdon Valley, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calliditas Therapeutics AB

Developing high-value, global products for patients with significant unmet medical needs in niche indications

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.